Loading clinical trials...

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Clinical Trials | Clareo Health

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

NCT06818643•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
•If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
•If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
•If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

Exclusion Criteria

•Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
•Has uncontrolled significant cardiovascular disease or cerebrovascular disease
•Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
•Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
•Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
•Known additional malignancy that is progressing or has required active treatment within the past 2 years
•Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
•Active infection requiring systemic therapy, with exceptions
•History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
•Has HBV or HCV infection

Locations (42)

The University of Alabama at Birmingham ( Site 1005)

Birmingham, Alabama, United States

University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)

Miami, Florida, United States

John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)

Hackensack, New Jersey, United States

Virginia Commonwealth University ( Site 1008)

Richmond, Virginia, United States

Centro de Estudios Clínicos SAGA ( Site 0033)

Santiago, Region M. de Santiago, Chile

FALP ( Site 0031)

Santiago, Region M. de Santiago, Chile

Pontificia Universidad Catolica de Chile ( Site 0032)

Santiago, Region M. de Santiago, Chile

Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)

Santiago, Region M. de Santiago, Chile

Peking University First Hospital ( Site 0180)

Beijing, Beijing Municipality, China

Chongqing Cancer Hospital ( Site 0186)

Chongqing, Chongqing Municipality, China

Key Dates

Start Date

March 25, 2025

Primary Completion Date

October 25, 2028

Completion Date

March 25, 2031

Last Updated

February 19, 2026

Enrollment

270

ESTIMATED participants

Conditions

Advanced Solid TumorsMalignant Neoplasm

Interventions

MK-3120

BIOLOGICAL

Contacts

Toll Free Number

CONTACT

1-888-577-8839 Trialsites@msd.com

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors